Studies on the Anticoagulant Action of Aprotinin (“Trasylol”)^[*]

Summary

Studies were undertaken to localize the site of the anticoagulant action of Aprotinin (“Trasylol”). Contact activation studies using either kaolin or contact product eluted from celite demonstrated that Aprotinin had greatest inhibitory action against the interaction of a surface with the contact factors, but some inhibition of formed contact product was also noted. In addition, Aprotinin was found to have a slight anticoagulant action against activated factor IX prepared by incubation of contact product with a calcium phosphate eluate from serum. No inhibitory action in pharmacological doses was demonstrated against activated factor X or later stages in the coagulation sequence.

It was concluded that Aprotinin is a relatively weak anticoagulant in doses liable to be obtained in vivo during therapeutic infusions.

• References

• 1 Amris G. J. Inhibition of fibrinolytic and thromboplastic activity by Trasylol. Scand. J. Haemat 03: 19 1966;
• 2 Amris G. J, Hilden M. Inhibition of thromboplastic activity by Trasylol. Scand. J. Haemat 04: 3 1967;
• 3 Beck E, Schmutzler R, Duckert F. Inhibition of fibrinolysis and fibrinogenolysis in man: comparison of E-aminocaproic acid and kallikrein inhibitor. Thrombos. Diathes. haemorrh. (Stuttg) 10: 106 1963;
• 4 Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path 06: 23 1953;
• 5 Biggs R, Nossel H. L. Tissue extract and the contact reaction in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg) 06: 1 1961;
• 6 Blombäck B, Blombäck M, Olsson P. Action of a proteolytic enzyme inhibitor on blood coagulation in vitro. Thrombos. Diathes. haemorrh. (Stuttg) 18: 190 1967;
• 7 Dubber A. HG, McNicol G. P, Uttley D, Douglas A. S. In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor. Brit. J. Haemat 14: 31 1968;
• 8 Gormsen J, Josephsen P. The effect of Trasylol on blood coagulation after intravenous injection. Thrombos. Diathes. haemorrh. (Stuttg) 17: 51 1967;
• 9 Henderson E. S, Rapaport S. I. The thrombotic activity of activation product. J. clin. Invest 41: 235 1962;
• 10 Mammen E. F. Ann. N.Y. Acad. Sci. 146: 713 1968;
• 11 Marx von R, Clemente P, Werle E, Appel W. Über die Wirkung von ProteinaseinhibitorPräparaten (Leber- und Parotisinhibitor) auf die extravasale Fibrinolyse, Fibrinogenolyse und Blutgerinnungskonstanten im Menschenblut. Blut 09: 164 1963;
• 12 Nordstrom S, Blombäck B, Blombäck M, Olsson P, Zetterquist E. Experimental investigations on the antithromboplastic and antifibrinolytic activity of Trasylol. Ann. N.Y. Acad. Sci 146: 701 1968;
• 13 Nordstrom S, Olsson P, Blombäck M. Thromboplastin-induced hypercoagulability and its prevention. Nature (Lond) 206: 632 1965;
• 14 Nossel H. L. The Contact Phase of Blood Coagulation. Ch. 7. Blackwell; Oxford: 1964
• 15 Nossel H. L. The Contact Phase of Blood Coagulation. 50 Blackwell; Oxford: 1964
• 16 Owren P. A. A quantitative one-stage method for the assay of prothrombin. Scand. J. clin. Lab. Invest 01: 81 1949;
• 17 Prentice C. RM, Ratnoff O. D, Breckenridge R. T. Experiments on the nature of the prothrombin-converting principle : alteration of proaccelerin by thrombin. Brit. J. Haemat 13: 898 1967;
• 18 Proctor R. R, Rapaport S. I. The partial thromboplastin time with kaolin. Amer. J. clin. Path 36: 212 1961;
• 19 Rapaport S. I, Hjort P. F, Patch M. J, Jeremic M. Consumption of serum factors and prothrombin during intravascular clotting in rabbits. Scand. J. Haemat 03: 59 1966;
• 20 Ratnoff O. D, Davie E. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI). Biochemistry 01: 677 1962;
• 21 Steichele D. F, Herschlein H. J. Zur antifibrinolytischen Wirkung des Trypsin-Kallikrein- Inactivators. Med. Welt 1961; 2170.
• 22 Wessler S, Reimer S. M. The role of human coagulation factors in serum-induced thrombosis. J. clin. Invest 39: 262 1960;